EASL 2013 ELPA eventSymposium: compassionate use in hepatitis C. Photo by Sylvie Beaumont / infohep.orgNew! Infohep.orgInfohep.org launched at the International Liver Congress. Hepatitis newsSign up for our monthly hepatitis news bulletin. infohep news Interferon treatment for HBV Asian and Caucasian patients respond similarly to pegylated interferon for chronic hepatitis B Keith Alcorn / 20 May 2013 Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at ... Treatment in liver transplanted Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common Liz Highleyman / 17 May 2013 Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at ... Interferon-free regimens ACH-3102 and sovaprevir show potent activity, high barrier to resistance in early studies Keith Alcorn / 14 May 2013 Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented ... Triple therapy Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... Interferon-free regimens Daclatasvir plus interferon-based therapy cures more genotype 2/3 hepatitis C patients Liz Highleyman / 07 May 2013 Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, ... Antiviral therapy Truvada works best for immune-tolerant hepatitis B patients, but do they need treatment? Liz Highleyman / 07 May 2013 A combination of tenofovir and emtricitabine (the drugs in the combination pill Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over four years for people with inactive or immune-tolerant disease, ... Finance, funding & health economics Early hepatitis C treatment may not be cost-saving in France - but early diagnosis will save money Keith Alcorn / 07 May 2013 Treating hepatitis C earlier than recommended by current French and European treatment guidelines, before the development of severe liver fibrosis, may not result in substantial cost savings even if the price of direct-acting ... Interferon-free regimens Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination Liz Highleyman / 02 May 2013 An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a ... Triple therapy Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C Keith Alcorn / 01 May 2013 A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Peter Ferenci ... Triple therapy Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80% Keith Alcorn / 01 May 2013 A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Michael Manns of ... View more > Editors' picks from other sources Treatment issues Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? NATAP / 16 May 2013 Cirrhosis Probiotics Found To Reduce Hepatic Encephalopathy In Cirrhotic Patients Liver Disease News from Medical News Today / 30 April 2013 Cirrhosis New Advances In The Management Of Patients With Cirrhosis Liver Disease News from Medical News Today / 30 April 2013 Treatment in liver transplanted Drug Trio Helps Treat HCV After Transplant MedPage Today Gastroenterology / 30 April 2013 Antiviral therapy HIV Drug Combo Shows Promise in Hepatitis B MedPage Today Gastroenterology / 28 April 2013 Interferon-free regimens Successful Hep-C Combo May Elude Patients as Gilead Goes Solo Bloomberg BusinessWeek / 28 April 2013 Testing for liver fibrosis & cirrhosis Liver Imaging Tests Vie to Replace Biopsy MedPage Today Gastroenterology / 27 April 2013 Side effects Anemia Top Side Effect of HCV Antivirals MedPage Today Gastroenterology / 27 April 2013 Triple therapy INCIVO® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for Twice Daily Dosing for Treatment of Genotype-1 Hepatitis C Virus Janssen press release / 26 April 2013 Hepatocellular carcinoma (HCC) Novel screening tests for liver cancer Medical Xpress / 26 April 2013 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive